Tudor Investment Corp ET AL Buys $7.17M Stake in Summit Therapeutics

Got story updates? Submit your updates here. ›

Tudor Investment Corp ET AL, a prominent hedge fund, has purchased a new stake of 347,241 shares in Summit Therapeutics PLC (NASDAQ:SMMT), valued at approximately $7.17 million. This move comes as several other institutional investors have also increased their positions in the biotech company in recent quarters.

Why it matters

Summit Therapeutics is developing novel treatments for serious and life-threatening diseases, including Clostridioides difficile infections. The company's lead drug candidate, ridinilazole, has received Fast Track and Qualified Infectious Disease Product designations from the U.S. FDA, indicating its potential to address an unmet medical need. The increased institutional investment suggests growing confidence in Summit's pipeline and future prospects.

The details

According to the company's recent SEC filing, Tudor Investment Corp ET AL purchased the 347,241 shares of Summit Therapeutics in the third quarter. This new stake represents a significant investment for the hedge fund, valued at around $7.17 million. The filing also reveals that other major institutional investors, such as Vanguard Group Inc. and Bank of America Corp DE, have also increased their positions in Summit Therapeutics in recent quarters.

• Tudor Investment Corp ET AL purchased the new stake in Summit Therapeutics during the third quarter of the year.
• The SEC filing disclosing the transaction was made on April 8, 2026.

What’s next

Investors will be closely watching Summit Therapeutics' progress with its lead drug candidate, ridinilazole, as it continues through clinical trials and potential regulatory approval.